diethyl 4-chloro-1-oxobutanephosphonate | 97538-78-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: diethyl 4-chloro-1-oxobutanephosphonate
• 英文别名: 4-Chloro-1-diethoxyphosphorylbutan-1-one
• CAS: 97538-78-8
• 化学式: C₈H₁₆ClO₄P
• 分子量: 242.639
• InChiKey: VJYWJLDJUWUBES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  diethyl 4-chloro-1-oxobutanephosphonate 在 吡啶 、 甲酸 、 盐酸羟胺 、 sodium carbonate 、 锌 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 12.0h， 生成 diethyl pyrrolidin-2-ylphosphonate
  参考文献：
  名称：

  Subotkowski, Witold; Tyka, Roman; Mastalerz, Przemyslaw, Polish Journal of Chemistry, 1983, vol. 57, # 10-12, p. 1389 - 1391

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯丁酰氯 、 亚磷酸三乙酯 生成 diethyl 4-chloro-1-oxobutanephosphonate
  参考文献：
  名称：

  Synthesis and Study of Alendronate Derivatives as Potential Prodrugs of Alendronate Sodium for the Treatment of Low Bone Density and Osteoporosis

  摘要：

  Alendronate derivatives were evaluated as potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic exposure after oral administration. An investigation of the chemical behavior of alendronate derivatives led to development of practical synthetic strategies and prediction of each structural class's prodrug potential. Pharmacokinetic studies of N-myristoylalendronic acid revealed that 25% have been converted in vivo after iv administration in rat, providing an important proof-of-concept for this strategy.

  DOI：

  10.1021/jm060398v

文献信息

• SUBOTKOWSKI, W.;TYKA, R.;MASTALERZ, P., POL. J. CHEM., 1983, 57, N 10-12, 1389-1391
  作者：SUBOTKOWSKI, W.、TYKA, R.、MASTALERZ, P.

  DOI：——

  日期：——
• Subotkowski, Witold; Tyka, Roman; Mastalerz, Przemyslaw, Polish Journal of Chemistry, 1983, vol. 57, # 10-12, p. 1389 - 1391
  作者：Subotkowski, Witold、Tyka, Roman、Mastalerz, Przemyslaw

  DOI：——

  日期：——
• Synthesis and Study of Alendronate Derivatives as Potential Prodrugs of Alendronate Sodium for the Treatment of Low Bone Density and Osteoporosis
  作者：Petr Vachal、Jeffrey J. Hale、Zhe Lu、Eric C. Streckfuss、Sander G. Mills、Malcolm MacCoss、Daniel H. Yin、Kimberly Algayer、Kimberly Manser、Filippos Kesisoglou、Soumojeet Ghosh、Laman L. Alani

  DOI：10.1021/jm060398v

  日期：2006.6.1

  Alendronate derivatives were evaluated as potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic exposure after oral administration. An investigation of the chemical behavior of alendronate derivatives led to development of practical synthetic strategies and prediction of each structural class's prodrug potential. Pharmacokinetic studies of N-myristoylalendronic acid revealed that 25% have been converted in vivo after iv administration in rat, providing an important proof-of-concept for this strategy.